Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

PK Parameter: Tmax for Asciminib

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hour (hr)
Interval / dispersion
Full Range
Time frame
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

What was measured

Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.

Analysis population: Pharmacokinetic (PK) analysis set (PAS) included all participants who provided at least one evaluable PK concentration.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib15

Reported measurements

Source class 1
Values in hour (hr) · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Asciminib1.92Not reported0.9833.33Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.983
        upper Limit
        3.33
        value
        1.92
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
Time to reach maximum (peak) plasma concentration after dose administration (time). Actual sampling times were taken into consideration for the pharmacokinetic analysis.
dispersion Type
Full Range
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
param Type
MEDIAN
population Description
Pharmacokinetic (PK) analysis set (PAS) included all participants who provided at least one evaluable PK concentration.
reporting Status
POSTED
time Frame
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
title
PK Parameter: Tmax for Asciminib
type
SECONDARY
unit Of Measure
hour (hr)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice